Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
Tan, QY; Dai, LY; Wang, YR; Liu, SX; Liang, T; Luo, RR; Wang, SS; Lou, N; Chen, HZ; Zhou, Y; Zhong, QF; Yang, JL; Xing, PY; Hu, XS; Liu, YT; Zhou, SY; Yao, JR; Wu, D; Zhang, ZS; Tang, L; Yu, XB; Han, XH; Shi, YK
Shi, YK (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.;Han, XH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, NMPA Key Lab Clin Res & Evaluat Drug, Peking Union Med Coll Hosp,Clin Pharmacol Res Ctr, State Key Lab Complex Severe & Rare Dis,Beijing K, Beijing 100032, Peoples R China.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022; 71 (7): 1681
